ABBV Options Signal Bullish Bias: Target $230 Calls as Earnings Volatility Looms

• ABBV surges 2.16% to $225.67, trading near 200D MA resistance at $224.29
• Call open interest dominates at $230, $235, and $240 strikes for next Friday (Feb 20)
• Put/call ratio of 0.89 shows bullish skew, with $200 puts as top hedge
• Earnings release on Feb 10 and Horizon acquisition closing in Q2 2026 add catalysts

The market is pricing in a breakout: ABBV’s options activity and technicals align on a bullish setup. With call open interest spiking at key strikes and the stock testing upper Bollinger Bands, traders are positioning for a move above $230. But here’s what you need to watch before jumping in.Options Sentiment and Implied Volatility

ABBV’s options chain tells a clear story. For next Friday’s expiration, ABBV20260220C230 and ABBV20260220C240 calls lead with 3,355 and 3,084 open contracts—nearly 10x the put activity at $200. This isn’t just noise: the 0.89 put/call ratio (call OI: 122,446 vs put OI: 109,356) shows investors are betting on upside. The $230 strike is especially telling—it sits just 2.8% above current price, suggesting a near-term target. Meanwhile, $200 puts (OI: 6,328) act as a floor for downside protection, but with RSI at 53.9 and MACD flipping positive, the bias is clearly northbound.

News-Driven Narrative

ABBV’s fundamentals back the options chatter. The $28.5B Horizon acquisition and $1.5B buyback program signal management’s confidence in the stock. Recent earnings beat (4.5% surge) and Imbruvica’s Japanese approval add momentum. But don’t ignore the risks: Humira’s 12% sales drop from generics is real. The CEO transition in 2026 could also create short-term jitters. Still, the market seems to value growth bets over near-term headwinds—hence the call-heavy positioning.

Actionable Trading OpportunitiesFor options traders: Buy ABBV20260220C230 calls at $2.15–$2.25 per contract. With ABBV trading at $225.67, a $230 strike gives 1.9% breakeven (225.67 + 2.25). If the stock holds above $220.24 (middle Bollinger Band), these calls could run. For a hedge, buy ABBV20260220P220 puts at $1.80–$1.90.For stock traders: Consider entries near $225.67 with a target at $230 (30D resistance) and $235 (next key level). Use $220.24 as a stop-loss. If ABBV closes above $226.79 (intraday high), it could test $227.18 (Bollinger upper band) and trigger a short-term breakout.Volatility on the Horizon

ABBV’s next 30 days will be pivotal. The Feb 20 expiration lines up with the Horizon acquisition’s expected close (Q2 2026) and Q1 2026 earnings (due March). With call OI concentrated near $230–$240, a pop above $230 could ignite a parabolic move. But don’t ignore the $213.30 lower Bollinger Band—it’s a critical support level. For now, the data says: buy the bounce, but keep your stops tight. The market’s betting on a bull case, but the bear is lurking if Humira’s erosion accelerates. Your call—literally.